

**Alaska Medicaid Pharmacy and Therapeutics Committee  
Meeting September 15, 2023**

**Please note, as a result of COVID-19 this meeting will be available via teleconference only.**

**Please register for the meeting by using the link below:**

[https://magellanhealth.zoom.us/webinar/register/WN\\_RyJKBxD\\_QWWqm-GbKQ1H7A](https://magellanhealth.zoom.us/webinar/register/WN_RyJKBxD_QWWqm-GbKQ1H7A)

If you are calling in only through the webinar:

\*6 to Toggle mute/unmute and \*9 to Raise Hand

After registering, you will receive a confirmation email containing information about joining the webinar.

**Agenda**

Public Call in toll free: 1-877-853-5247

- 1. Call to Order – Chair 8:00 am**
- 2. Roll Call 8:05 am**
- 3. Public Comment**

The Department’s methods for class review are to better utilize the time of the P&T Committee. Classes shown in **Red** are *new classes/new drugs* and **Blue** are classes where *\*\*new information exists and industry testimony will be taken*. Classes shown in **Green** are classes with no significant changes have been noted and no industry testimony will be taken.

*\*\*New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.*

- 4. Class review, discussion & vote.**

<b>AK Treatment</b>	<b>Drug Class</b>	<b>Status</b>
<b>Gastrointestinal</b>	Antiemetic-Antivertigo Agents	<b>GREE</b>
	GI Motility & Irritable Bowel Syndrome, Chronic	<b>BLUE</b>
	Ulcerative Colitis	<b>GREE</b>
	Cytokine & Cell-Adhesion Molecules (CAM) Antagonist – <i>GI indicated</i>	<b>RED</b>
	Proton Pump Inhibitors	<b>BLUE</b>
<b>Endocrine/ Metabolic</b>	Antihyperuricemics	<b>BLUE</b>
	Progestins for Cachexia	<b>GREE</b>
	Growth Hormone	<b>GREE</b>
	Androgenic Agents, Topical	<b>GREE</b>
	Bone Resorption Inhibitors	<b>BLUE</b>
	Gluca gon Agents	<b>GREE</b>
	Hypoglycemics, Metformin	<b>GREE</b>
	Hypoglycemics, Alpha-Glucosidase Inhibitors	<b>GREE</b>
	Hypoglycemics, SGLT2 Inhibitors	<b>RED</b>
	Hypoglycemics, Meglitinides	<b>GREE</b>
	Hypoglycemics, Thiazolidinedione (TZD) and Combinations	<b>GREE</b>
	Hypoglycemics, Dipeptidyl Peptidase-4 Inhib. (DPP-4) and Combinations	<b>GREE</b>
	Hypoglycemics, Gluca gon-like Peptide-1 (GLP-1) and Combinations	<b>BLUE</b>
	Rapid-Acting Insulins	<b>BLUE</b>
	Regular Insulins	<b>GREE</b>
	Intermediate Insulins	<b>GREE</b>
	Rapid/Intermediate-Acting Combination Insulins	<b>GREE</b>
	Regular/Intermediate-Acting Combination Insulins	<b>GREE</b>
	Long-Acting Insulins	<b>BLUE</b>
Phosphate Binders	<b>GREE</b>	
<b>Antiretrovirals</b>	HIV/AIDs	<b>RED</b>
<b>Single Class Review</b>	Movement Disorders	<b>BLUE</b>
	Continuous Glucose Monitors	<b>GREE</b>

**Break as needed – 15 minutes**

- 7. Review minutes from April 2023 meeting**
- 8. Comments from Committee Members or Chair**
- 9. Adjourn**

*Next Meeting Date: November 17, 2023*